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ABSTRACT
Tumour heterogeneity leads to variable clinical response and inaccurate 
diagnostic and prognostic assessment. Cancer stem cells (CSCs) represent a 
subpopulation responsible for invasion, metastasis, therapeutic resistance, and 
recurrence in many human cancer types. However, the true identity of colorectal 
cancer (CRC) SCs remains elusive. Here, we aimed to characterize and define the gene 
expression portrait of CSCs in CRC-model SW403 cells. We found that ALDH+ positive 
cells are clonogenic and highly proliferative; their global gene expression profiling-
based molecular signature revealed gene enrichment related to DNA damage, MAPK, 
FAK, oxidative stress response, and Wnt signalling. ALDH+ cells showed enhanced 
ROS stress resistance, whereas MAPK/FAK pathway pharmacologic inhibition limited 
their survival. Conversely, 5-fluorouracil increased the ALDH+ cell fraction among the 
SW403, HCT116 and SW620 CRC models. Notably, analysis of ALDH1A1 and POU5F1 
expression levels in cohorts of 462 or 420 patients for overall (OS) or disease-free 
(DFS) survival, respectively, obtained from the Cancer Genome Atlas CRC dataset, 
revealed strong association between elevated expression and poor OS (p = 0.006) and 
poor DFS (p = 0.05), thus implicating ALDH1A1 and POU5F1 in CRC prognosis. Our 
data reveal distinct molecular signature of ALDH+ CSCs in CRC and suggest pathways 
relevant for successful targeted therapies and management of CRC.
www.impactjournals.com/oncotarget/              Oncotarget, 2018, Vol. 9, (No. 17), pp: 13551-13564
INTRODUCTION
Cancer represents the second leading cause of 
morbidity worldwide. GLOBOCAN 2012 estimated 
14.1 million new cancer cases and 8.2 million cancer 
deaths occurred in 2012 across the globe. Among these, 
colorectal cancer (CRC) comprises the third most common 
cancer with 1.4 million new cases and was responsible 
for 693,900 deaths in 2012, with higher mortality rate 
in males compared to females [1, 2]. The most common 
treatment for localized CRC is surgical removal; however, 
patients with CRC often presented with metastatic disease 
or exhibit high probability of developing disseminated 
disease during their lifetime [3]. Consistent with this, 
the leading cause of CRC mortality is the failure of most 
therapies in patients with metastatic disease. To reduce 
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mortality from CRC, it is therefore important to develop 
novel approaches based on the cellular and molecular 
phenotyping of CRC. Notably, our previous study has 
revealed multiple deregulated signalling pathways in 
CRC and suggested targeting those networks as a potential 
therapeutic strategy for CRC [4]. 
Treatment choices for patients with CRC assume 
homogeneity in tumour mass; therefore it is plausible that 
conventional chemotherapy and radiotherapy sometimes 
fail in tumour eradication. Alternatively, several studies 
have demonstrated that solid tumours including CRC 
exhibit cellular heterogeneity [5, 6], which may reflect 
different origin of cells at the time of tumour origination 
[7]. Furthermore, recently the presence within solid 
tumours of a minor subset of cells termed cancer stem-
like cells (CSCs) or tumour-initiating cells (TICs), which 
exhibit self-renewal and differentiation capabilities, has 
been demonstrated and suggested to be responsible for 
tumour maintenance, metastasis and drug resistance [6, 
8, 9]. Although normal tissue stem cells (SCs) and CSCs 
share certain characteristics, they exhibit significant 
differences in their differentiation potential and their 
microenvironmental niches [10, 11]. 
A number of surface markers e.g. CD133 
(prominin-1), CD44, and CD29 have been reported as 
potential markers for different types of CSCs [8]; however, 
these CD antigens also exist on normal stem cells and 
thus are of low specificity [12, 13]. In particular, aldehyde 
dehydrogenase 1 (ALDH1) has been reported as a marker for 
CSCs in a number of cancers [14, 15]. While there are three 
different isoforms for ALDH1 (ALDH1A1, ALDH1A2, and 
ALDH1A3), ALDH1 activity is predominantly attributed 
to ALDH1A1 isotype [11]. ALDH1A1-expressing CSCs 
from breast, lung, head and neck squamous cancer, 
possess tumour-initiating capabilities, suggesting a role in 
supporting tumour proliferation and maintenance [16–18]. 
The relevance of CSCs in cancer has been demonstrated 
in studies aimed at targeting CSC subpopulations and 
their signalling pathways [6, 9, 19]. In one study, patients 
with rectal adenocarcinoma (n = 64) who received 
preoperative radiochemotherapy showed high expression 
levels of different CSC markers—CD44, LGR5, CD166, 
and ALDH1—by immunostaining; additionally, in a Cox 
proportional hazards multiple regression model, ALDH1 
independently predicted poor prognosis in patients with 
CRC who received radiochemotherapy [20].
Although CSCs have been identified in many 
different types of solid tumours, the identity of 
ALDH+ CSCs and their molecular signature as well 
as their clonogenic and drug resistance properties are 
poorly characterized. In the current study, we utilized 
fluorescence activated cell sorting (FACS) and isolated the 
ALDH1+ and ALDH1− populations from the SW403 CRC 
cell model, characterised their molecular and functional 
phenotype, and subsequently validated these in additional 
CRC cell models. Our data identified several preferentially 
activated signalling pathways in ALDH1+ cells related to 
drug resistance with potential therapeutic implications that 
correlated with CRC prognosis.
RESULTS
Functional and molecular characterisation of an 
ALDH+ population in CRC SW403 cells. 
We employed the SW403 cell line as a cell model 
for CRC and assessed the expression of several colorectal 
CSC-associated markers [8] (Supplementary Figure 1). 
The cells exhibited heterogeneous expression of ALDH 
(7%), LGR5 (4%), and CD90 (3%), whereas CD133 
(99%), EpCAM (100%), CD44 (100%), and CD29 (100%) 
were expressed by the whole cell population. The SW403 
cells were CD24− (0%). The frequency of the ALDH+ 
population in SW403 cells was determined using an 
Aldefluor assay. As shown in Figure 1A, approximately 
7% of the cells were ALDH+, which decreased to <1% in 
the presence of  diethylaminobenzaldehyde (DEAB) (an 
ALDH inhibitor). Subsequently, we sorted both ALDH+ 
and ALDH− cell fractions using FACS. The purity of sorted 
cells was analysed by Aldefluor assay, which revealed 
more than 99% purity in the ALDH+ fraction, whereas the 
sorted ALDH− fraction showed minimal ALDH activity 
of <1.4% (Figure 1B). Further analysis demonstrated that 
the percentage of proliferating cells was higher in ALDH+ 
cells (day 6: 154% vs 100% and day 10: 124% vs 100%) 
compared to ALDH− cells, p < 0.0005 (Figure 1C). This 
decrease in relative proliferation rate between day 10 and 
day 6 could possibly be attributed to the re-expression 
of ALDH by ALDH- fraction in culture (Supplementary 
Figure 2). Concordantly, the number of colonies formed 
in the ALDH+ fraction was higher than that observed in 
the ALDH– fraction (Figure 1D and 1E). Taken together, 
our data demonstrated higher proliferation and clonogenic 
capability of the ALDH+ cells. We observed significant 
increase in a number of stem cell associated gene markers: 
KL4, BAX, PCNA, SMOC2, KITLG, NANOG, KLF5, and 
BST and decrease in the expression of CD133, CDH1, 
SOX4, and SOX2 in ALDH+ compared to ALDH− cells 
(Supplementary Figure 3). The expression of PLAU, 
SNAI1, BMI1, and LGR5 did not show significant change 
in ALDH+ compared to ALDH− cells. 
Global gene expression profiling reveals a 
distinct molecular profile of ALDH+ cells 
We subsequently performed global mRNA 
expression profiling comparing ALDH+ to ALDH− cells. 
As shown in Figure 2A, hierarchical clustering based on 
differentially expressed mRNAs revealed clear separation 
of ALDH+ from ALDH− cells. We observed 1015 up-
regulated and 1906 downregulated transcripts in ALDH+ 
cells compared to ALDH− cells (Supplementary Table 1). 
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The distribution of the top 20 enriched pathways for the 
up-regulated genes in ALDH+ cells is shown in Figure 2B. 
Among the highly enriched pathways were: DNA damage 
and oxidative stress response, MAPK, FAK, and Wnt 
signalling, and pluripotency. The expression levels of 
a selected group of genes related to Cell cycle, DNA 
damage, oxidative stress, Wnt and apoptosis pathways 
including CDC25B, CCND3, ATM, TP53AIP1, SOD3, 
CYP1A1, and POU5F1 were validated using quantitative 
reverse transcription polymerase chain reaction (qRT-
PCR) analysis (Figure 2C).
ALDH+ cells exhibit enhanced resistance to 
5-Fluorouracil (5-FU) drug treatment  
Microarray data revealed enrichment in DNA 
damage and oxidative stress response pathways in 
ALDH+ cells; thus, we hypothesized that ALDH+ cells 
Figure 1: Proliferation and clonogenic potential of colorectal cancer ALDH+ cells. (A) Frequency of ALDH+ cells in the 
SW403 CRC model measured using the Aldefluor® assay and flow cytometry. The shift of fluorescence defined the population in R3 
(Right panel) presenting positive ALDH1 activity and in R5 presenting Negative ALDH1 activity. The highly positive sub-population 
(~5%) and ALDH− cells were collected using the Astrios® cell sorter. (B) Purity assessment was performed on sorted ALDH+ positive and 
negative subpopulations using the Aldefluor assay where the percentage of ALDH+ was ~99% compared to the negative fraction ~1.4%. 
(C) Proliferation of ALDH+ positive cells compared to ALDH− cells over time. (D and E) Clonogenic assay showing marked increase 
in the colony forming capability of ALDH+ compared to ALDH− cells. Plates were stained with Diff-Quik stain set on day 10. Wells 
are representative of two independent experiments for each condition. (e) The two-tailed t-test was used to compare different groups. 
**p < 0.005; ***p < 0.0005.
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Figure 2: Preferential activation of multiple signalling pathways in ALDH+ cells. (A) Hierarchical clustering of ALDH+ 
vs ALDH− subpopulations based on differentially expressed mRNA levels. Each column represents one replica and each row represents 
a transcript. Expression level of each gene in a single sample is depicted according to the colour scale. (B) Pie chart illustrating the 
distribution of the top 20 pathways designations for the differentially expressed genes in ALDH+ cells. The pie size corresponds to the 
number of matched entities. (C) Expression levels of selected genes from the microarray data were validated using qRT-PCR in ALDH1+ 
compared to ALDH− cells. Data are presented as the means ± S.D, n = 3. *p < 0.05; **p < 0.005; ***p < 0.0005.
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exhibit enhanced resistance to 5-FU, a chemotherapeutic 
drug frequently used to treat patients with CRC. 5-FU 
treatment of SW403 cells led to a dose-dependent increase 
in the percentage of ALDH+ cells from 7% in controls to 
24% at a concentration of 12.5 µM (Figure 3A and 3B). 
In addition, as shown in Figure 3C, the acridine orange/
ethidium bromide (AO/EtBr) assay revealed a higher 
percentage of cell death (apoptosis and necrosis) in the 
ALDH1− compared to the ALDH1+ fraction in the SW403 
model in response to 5-FU (1.25 and 2.5 µM) treatment. 
To extrapolate our findings to additional colorectal 
cancer cell models, a panel of colorectal cancer cell 
lines: COLO320, HT29, HCT116, and SW620 were 
exposed to different concentrations of 5-FU for 5 days at 
a concentration of 6.2 and 12.5 µM and the percentages of 
ALDH+ cells were determined using the Aldefluor assay. 
As shown in Figure 4A and 4B, significant increases in 
the percentages of ALDH+ population were observed in the 
HCT116 (Control: 22%; 6.2 µM: 22.5%; 12.5 µM: 32%) 
and SW620 (Control: 4%; 6.2 µM: 8%; 12.5 µM: 8%) 
cells, whereas there were no significant changes in the 
percentage of ALDH+ population within the COLO320 
and HT29 models following 5-FU treatment. Therefore, it 
is plausible that 5-FU treatment targets mainly the ALDH− 
population, which leads to an increase in the ALDH+ 
fraction post-treatment. 
Inhibition of MAPK and FAK signalling 
pathways reduces the ALDH1+ cell fraction in 
the SW403 cell line
In addition to DNA damage and oxidative stress 
pathways, ALDH+ cell molecular signature revealed 
significant enrichment in genes within the MAPK and 
FAK signalling pathways (Figure 2B). Illustration of 
the FAK and MAPK pathways are shown with matched 
entities highlighted in Supplementary Figures 4 and 5, 
respectively. These data suggested a plausible role for 
MAPK and FAK signalling pathways in maintaining 
the ALDH+ population. SW403 cells were treated with 
Figure 3: ALDH+ cells show enhanced resistance to 5-fluorouracil. (A) Unsorted SW403 cells were exposed to 5-FU for 5 days, 
and subsequently the frequencies of ALDH+ cells were assessed using the Aldefluor assay, which revealed a dose-dependent increase in the 
proportion of ALDH+ cells (Control (7%), 5-Fu treated at 6.2 μM (19%), 12.5 μM (24%), and 25 μM (22%)), respectively. Experiments 
were normalized to the respective DEAB controls. (B) Quantification of the percentages of ALDH+ cells from (a). The two-tailed t-test 
was used to compare different treatment groups. **p < 0.005.; ***p < 0.0005. (C) Representative fluorescence images of sorted ALDH+ and 
ALDH− subpopulations [± different concentration (1.25 μM and 2.5 μM) 5-fluorouracil]. Cells were stained with acridine orange/ethidium 
bromide to detect apoptotic (cells with green condensed chromatin) and necrotic cells (red).
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MAPK (5 µM; PD98059) and FAK (5 µM; PF573228) 
small molecule inhibitors, and the ALDH1+ cell fraction 
was determined on day 5 post-treatment. As shown in 
Figure 5A and 5B, significant decreases in the ALDH1+ 
population were observed in both MAPK (1%) and FAK 
(3.4%) inhibitor-treated cells, compared to the dimethyl 
sulphoxide (DMSO) control (7%), suggesting a role for 
these two pathways in maintaining the CRC ALDH+ 
population. Whether MAPK/FAK inhibition promotes 
ALDH+ cell death or reduced ALDH expression remains 
to be investigated. 
ALDH1+ cells are more resistant to oxidative 
stress compared to ALDH1− cells
Hydrogen peroxide (H2O2) is a non-radical reactive 
oxygen species (ROS) that can activate nuclear transcription 
factors, such as NF-κB, p53, and AP-1 leading to the 
induction of pro-apoptotic or inhibitor of survival proteins 
[21]. The oxidative stress pathway is illustrated with 
matched entities highlighted in Figure 6A. As we found that 
the oxidative stress pathway was one of the top enriched 
pathways in ALDH1+ cells (Figure 2B), we examined 
Figure 4: ALDH+ fraction is more resistant to 5-FU in multiple CRC models. Drug sensitivity and enrichment analysis of 
ALDH+ populations in different CRC cell lines. (A) Different adenocarcinoma clones of CRC cell lines (COLO320, HT29, HCT116, 
and SW620) were treated with 5-FU for 5 days using different concentrations (6.2 µM and 12.5 µM), and subsequently the cells were 
stained with the Aldefluor assay to determine the frequencies of ALDH+ cells in 5-FU treated vs non-treated cells. Experiments were 
normalized with respective DEAB controls. (B) The two-tailed t-test was used to compare different treatment groups. *p < 0.05; **p < 0.005; 
***p < 0.0005.
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the effect of ROS on the ALDH+ cell fraction in SW403 
cells following exposure to H2O2 (50 µM) for 5 days. Our 
data revealed a significant increase in the ALDH+ fraction 
(14% ALDH+) compared to the control cells (7% ALDH+), 
suggesting that ALDH+ cells are more capable of surviving 
ROS-mediated oxidative stress (Figure 6B).
ALDH1 expression is a possible prognostic 
marker for CRC
To assess the clinical relevance of our findings, we 
examined the expression of ALDH1A1 and POU5F1 in 
a cohort of 462 patients for overall survival (OS) or 420 
patients for disease-free survival (DFS), obtained from 
the Cancer Genome Atlas CRC data set [22]. As shown in 
Figure 7, a strong association between elevated expression 
of ALDH1A1 or/and POU5F1 and poor OS (p = 0.006) 
and poor DFS (p = 0.05) was observed.
DISCUSSION
CSCs have been identified in a number of solid 
tumours including breast, colon, glioma, liver, lung, 
melanoma, ovarian, pancreatic, and prostate cancers. 
However, their biological relevance and functions within 
the tumour microenvironment remains under investigation 
and debate [8, 23]. The true identify of CSCs is also still 
uncertain, although a number of cellular proteins have 
been suggested as potential markers for CSCs [24]. Among 
these, CD133 (PROM1), and LGR5 have been suggested 
as potential markers for CRC CSCs [25, 26]. Notably, the 
frequencies of CD133+ or LGR5+ in CRC can reach >24%, 
which may question their specificity for identifying CSCs. 
ALDH, alternatively, has been suggested as a potential 
marker for normal colon as well as CRC SCs [27]. ALDH+ 
cells are few in number and limited to the normal crypt 
bottom, the expected location of SCs. An APC gene 
Figure 5: Pharmacological inhibition of MAPK and FAK significantly abrogates the ALDH+ population in the SW403 
CRC model. (A) Inhibition of MAPK ((5 μM, PD98059; Sigma; middle panel) or FAK ((5 μM, PF-573228; Sigma; right panel) for 
5 days reduces the proportion of ALDH+ cells in the SW403 model. (B) Quantitative analysis of the frequencies of ALDH+ cells from (a). 
The two-tailed t-test was used to compare the treatment group with the respective control. ***p < 0.0005.
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mutation that leads to epithelial development of adenoma 
is associated with increased number of ALDH1+ cells and 
their distribution beyond the crypt. Furthermore, ALDH1+ 
cells isolated from patients with CRC readily generated 
xenograft tumours with as low as 25 cells injected in vivo, 
whereas ALDH1− cells did not form tumours [27]. 
In the present study, we found a distinct molecular 
phenotype of ALDH+ cells, which suggests a number of 
biological characteristics relevant to understanding the 
biology of CRC and its response to therapy. Pathway 
analysis on the up-regulated genes in ALDH+ cells revealed 
significant enrichment in multiple signalling pathways 
including FAK, MAPK, DNA damage response, cell cycle, 
oxidative stress, and Wnt and pluripotency pathways. 
Concordant with the gene expression data, functional 
studies demonstrated a pivotal role for FAK and MAK 
Figure 6: ALDH+ cells exhibit enhanced resistance to oxidative stress. (A) Illustration of the oxidative stress pathway with 
matched entities highlighted and fold change in ALDH+ vs ALDH- indicated. (B) Significant increase in the frequencies of ALDH+ positive 
population in the SW403 cell line was observed post-exposure to H2O2 (50 µM). Quantitate analysis of the frequencies of ALDH
+ cells 
is shown in the right panel. Data are presented as the means ± S.D. Two-tailed t-test was used to compare treatment groups. **p < 0.005.
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signalling in the maintenance of ALDH+ cells. Some recent 
studies corroborate our findings. Blaj et al. demonstrated 
strong intra-tumoural heterogeneity with respect to 
activation of MAPK in CRC, with high MAPK activity 
restricted to the less-differentiated tumour cells located 
at the tumour leading edge [28]. Additionally, elevated 
expression of genes associated with MAPK and FAK 
signalling have been linked to epithelial-to-mesenchymal 
transition in CRC [29–32]. FAK is overexpressed and is 
activated in numerous advanced-stage solid tumours. In 
addition, FAK has been described as an important pathway 
in CSC self-renewal and cancer metastasis through both 
kinase-dependent and kinase-independent mechanisms [31]. 
In acute myeloid leukaemia, the FAK pathway regulates the 
expression of a number of cytokines (interleukin 6 (IL 6), IL 
8, stromal cell-derived factor 1, and angiopoietin 1), which 
are crucial for CSCs maintenance [33]. In animal models, 
small-molecule FAK inhibitors reduce tumour angiogenesis 
and FAK inhibitors are being developed for a possible role 
in cancer therapy [34].
We observed that ALDH+ cells were more resistant 
to 5-FU treatment and ROS exposure than ALDH− cells in 
several CRC cell models: SW403, HCT116, and SW620, 
suggesting a possible role in mediating drug resistance. In 
other human cancer models, CD133 positive CSCs were 
reported to contribute to glioma radioresistance through 
preferential activation of the DNA damage checkpoint 
and an increase in DNA repair ability [35]. Similarly, 
Lim et al. confirmed that glioma CSCs play an important 
role in radioresistance through initiation of DNA damage 
checkpoint proteins including ATM, SMC1, Chk1, Chk2, 
and p53 and increased DNA repair [36]. In our study, we 
observed ALDH+ cells to highly express a pluripotency 
gene (POU5F1, also referred to as OCT4) and superoxide 
dismutase 3 (SOD3), suggesting a role for these two genes 
in driving stemness and promoting cell survival under 
various stress conditions in ALDH+ cells. Concordant 
with our data, Chiou et al. reported that co-expression 
of POU5F1 and Nanog could enhance the malignancy 
of lung adenocarcinoma through induction of CSC-like 
properties and epithelial mesenchymal transition [37]. 
Similarly, Kumar and colleagues showed that POU5F1 
was able to promote dedifferentiation of melanoma cells 
into CSC-like cells [38]. Taken together, these findings 
clarify that POU5F1 plays a crucial role in maintaining 
the CSC phenotype in multiple human cancer types. 
The 5-year survival rate for patients with CRC 
having a localized tumour is approximately 90%, which 
is reduced to 70% for patients presenting with regional 
disease, and to 12% for those with metastases [39]. 
Therefore, a significant number of patients with CRC 
do not appear to benefit from standard chemotherapy, 
in particular in metastatic disease. Our in vitro data 
suggest that the presence of ALDH+ cells might 
predict the response of CRC to therapy. A number of 
studies have examined the relevance of ALDH1A1 as a 
biomarker in CRC. Nuclear expression of ALDH1A1 in 
a small subpopulation of patients was associated with 
shortened survival [40]. In a recent retrospective study, 
immunohistochemical expression of ALDH1 in epithelial 
cells was associated with poor prognosis, whereas its 
expression in stromal cells was associated with good 
prognosis in CRC [41]. In another study, high ALDH1 
expression was found as an independent prognostic factor 
associated with the 5-year OS and DFS and correlated 
with the tumor stage, lymph node status, and tumor 
differentiation [42]. These findings corroborate our 
findings of the association of ALDH1A1 expression with 
poor prognosis of the disease. Thus, our data revealed 
multiple enriched pathways within ALDH+ CRC cells 
that could potentially be targeted to eliminate the CSC 
population within the tumour, with the aim of treatment 
of disseminated disease and prevention of recurrences 
[9]. While the gene expression profiling and pathway data 
Figure 7: Altered expression of ALDH1A1 or POU5F1 is associated with poor OS and DFS in CRC. Kaplan–Meier curves 
illustrate the duration of OS (A) or DFS (B) according to the expression of ALDH1A1 and POU5F1 in a cohort of 462 patients (for OS) 
or 420 patients (for DFS) from the TCGA colorectal cancer dataset. Using log-rank analysis; the expression of ALDH1A1 or/and POU5F1 
was associated with poor OS (p = 0.006) and DFS (p = 0.05).
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presented in current study were generated using the non-
metastatic SW403 model, additional testing is needed to 
validate whether similar molecular signature also exists in 
metastatic colorectal cancer cell lines.    
MATERIALS AND METHODS
Cells lines and tissue culture
 The human colorectal cancer cell lines (SW403, 
COLO320, HT29, HCT116, and SW620) were obtained 
from American Type Culture Collection (ATCC, Manassas, 
VA, USA). Cells were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% foetal bovine 
serum (Gibco-Invitrogen, Waltham, MA, USA) and 100 
mg/l penicillin/streptomycin. All cells were maintained in 
a 37° C incubator with humidified 5% CO2.
Immunophenotyping by flow cytometry (FACS)
Immunophenotypic analysis was performed in 
accordance with our previously published protocols [12]. 
In brief, SW403 cells were harvested using 0.05% trypsin-
ethylenediaminetetraacetic acid and were washed twice in 
ice-cold phosphate buffered saline (PBS) supplemented 
with 0.5% bovine serum albumin and resuspended at 106 
cells/ml. Then, 10 μl of FITC-conjugated mouse anti-
human CD24 and CD90, PE-conjugated mouse anti-
human CD44, CD29, and EpCAM, or APC-conjugated 
mouse anti-human CD133 and LGR5 antibodies (from 
BD Biosciences, San Jose, CA, USA, and Miltenyi Biotec, 
Bergisch-Gladbach, Germany) was added to 100 μl of 
cell suspension (105 cells). Negative control staining was 
performed using FITC, PE, or APC-conjugated mouse 
IgG1 isotype control antibodies, respectively. Cells were 
incubated for 30 min at 4° C in the dark, washed with 
PBS, resuspended in 500 μl of PBS, and analysed using 
a Navios flow cytometer (Beckman Coulter, Brea, CA, 
USA). Living cells were gated in a dot plot of forward 
vs. side scatter signals obtained on linear scale. At least 
5000-gated events were acquired on a log fluorescence 
scale. Data were analysed using Kaluza software (1.2 
version, Beckman Coulter).
Aldefluor assay and ALDH +/− cell sorting
Aldefluor assay was performed in accordance with 
our previously published protocols [43]. The Aldefluor 
kit (Stem Cell Technologies, Vancouver, BC, Canada) 
was used to determine the percentage of cells with high 
aldehyde dehydrogenase (ALDH) enzymatic activity. 
Briefly, 106 cells were resuspended in Aldefluor assay 
buffer containing ALDH substrate as recommended by 
the manufacturer. As a negative control for all samples, 
an aliquot of ‘Aldefluor-exposed’ cells was immediately 
quenched using the ALDH inhibitor DEAB. After 30 min 
of incubation at 37° C, the cells were centrifuged and 
resuspended in 500 μl Aldefluor buffer and analysed using 
a Navios flow cytometer. Aldefluor staining was detected 
within the green fluorescence channel FL1. Samples 
treated with the inhibitor DEAB (+DEAB) were used as 
controls to establish the gates defining the ALDH+ region. 
DMSO control cells were used as an experimental control 
to compare drug or inhibitor treated cells, respectively. 
Kaluza software (1.2 version) was used to analyse the 
data. ALDH+/− cells were collected using a MoFlo Astrios 
cell sorter (Beckman Coulter). The collected cells were 
directly used for further experiments. 
Small molecule inhibitor experiments
Unsorted SW403 cells were exposed for 5 days to 
MAPK (5 µM; PD98059) and FAK (5 µM; PF573228) 
inhibitors, whereas oxidative stress was induced using 
H2O2 (50 µM). On day five, the cells were washed and the 
percentage of ALDH+ cells were analysed by the Aldefluor kit.
Gene expression microarray 
RNA isolation and gene expression analyses were 
carried out as described in our previously published 
manuscripts [44, 45]. In brief, RNA was isolated using the 
Total Tissue RNA Purification Kit from Norgen-Biotek 
Corp. (Thorold, ON, Canada) and was quantified using 
NanoDrop 2000 (Thermo Scientific, Wilmington, DE, 
USA). Total RNA was labelled and then hybridized to the 
Agilent Human SurePrint G3 Human GE 8 × 60 k mRNA 
microarray chip (Agilent Technologies, Santa Clara, CA, 
USA). All microarray experiments were conducted at the 
Microarray Core Facility (Stem Cell Unit, Department of 
Anatomy, King Saud University College of Medicine). 
Data were subsequently normalized and analysed using 
GeneSpring 13.0 software (Agilent Technologies). Pathway 
analyses were conducted using the Single Experiment 
Pathway analysis feature in Gene Spring 13.0 (Agilent 
Technologies). Twofold cut-off with p < 0.02 was used. 
Gene validation using qRT-PCR
Gene expression levels were validated in sorted 
SW403 ALDH+ and ALDH− cells using an RT-PCR assay 
as described previously [44]. In brief, SYBR Green-based 
qRT-PCR was performed using an Applied Biosystems 
ViiA 7 Detection system (Foster City, CA, USA). Then, 
500 ng of total RNA was reverse transcribed using a High 
Capacity cDNA Reverse Transcript Kit (Part No: 4368814; 
ABI) according to the manufacturer’s protocol. Relative 
levels of mRNA were determined from cDNA using 
quantitative real-time PCR (Applied Biosystems ViiA 
7 Systems). Primer sequences used in the current study 
are listed in Table 1. The expression level was calculated 
relative to GAPDH as a control. 
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Measurement of cell proliferation and clonogenic 
assay
The proliferation of sorted ALDH+ and ALDH− cells 
was determined using an Alamar Blue assay as previously 
described [4]. Briefly, 3000 cells were cultured in a 96-well 
plate and proliferation was measured at the indicated time 
points by adding 10% volume Alamar Blue assay reagent 
and measuring absorbance at 570 λ. The colony forming 
ability of both ALDH+ and ALDH− cells was determined 
using a clonogenic assay as previously described [44]. 
Briefly, both SW403 SW403 ALDH+ and ALDH− cells 
were seeded in 12-well plates in different serial dilution 
(1:2 to 1:16). Initial seeding density was 0.015 × 106 cells 
per well, and plates were incubated at 37° C under 5% CO2 
for 10 days. The plates were then washed and stained with 
Diff-Quik stain set (Siemens, Malvern, PA, USA), scanned, 
and the number of colonies was counted using Image-Pro 
Plus software (Media Cybernetics). The experiment was 
performed twice in duplicate. The fraction of surviving cells 
was estimated by comparing the number of colonies formed 
in ALDH+ to that in the ALDH− cells. 
Measurement of apoptosis
A fluorescence-based apoptosis assay was employed 
in cells following exposure to different concentration of 
5-Fluorouracil (2.5 to 1.25 µM), using the AO/EtBr staining 
method as previously described [44]. Briefly, cells were 
stained with dual fluorescent staining solution (1.0 µl) 
containing 100 µg/ml AO and 100 µg/ml EtBr (AO/EB, 
Sigma, St. Louis, MO, USA). Cells were gently mixed with 
AO/EtBr (1:100) dye solution for 1 min; afterwards, the cells 
were observed and photographed under a Nikon Eclipse 
Ti fluorescence microscope (Nikon, Tokyo, Japan). Cells 
cultured without drug treatment were considered control. 
Statistical analysis
Statistical analyses and graphing were performed 
using Microsoft excel 2010 and GraphPad Prism 6.0 
software (GraphPad, San Diego, CA, USA). P-values 
were calculated using a two-tailed t-test. 
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